Login / Signup

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?

Andrew J LasterGordon K LamHeather S GladueAhmad A KashifErin P SiceloffVirginia D LackeyCheryl R RobertsonAshley L TociLeonard H Calabrese
Published in: RMD open (2022)
Keyphrases
  • coronavirus disease
  • sars cov
  • rheumatoid arthritis
  • multiple sclerosis
  • oxidative stress
  • drug induced
  • respiratory syndrome coronavirus